Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Enrollments for Phase 2B Study

<< Previous

Bullboard Posts

Next >>

Comment by Raddnaron Sep 02, 2020 2:39pm

90 Views

Post# 31495646

RE:RE:Enrollments for Phase 2B Study

Fortunately, studies aren’t done that way or doctors would be able to take advantage of insider trading. The doctors and nurses administrating agnpf’s ifenprodil study for both covid and chronic cough don’t know which patients are receiving ifenprodil. The trial is 3 part, 1 is a higher dose, 1 is a lower dose, and 1 is nothing.

Once the trials are compelte, the patient data is sent to AGNPF and they’re able to determine the outcome.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec